News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck KGaA Falls; EU Rejects Erbitux for Lung Cancer
July 27, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Merck KGaA slumped the most in 14 years in Frankfurt trading after the European Union rejected its Erbitux drug for a form of lung cancer, denting growth prospects for the company’s top-selling oncology treatment.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
CDC
NIH’s Jay Bhattacharya Steps In as Acting CDC Chief
February 18, 2026
·
1 min read
·
Annalee Armstrong
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
·
3 min read
·
Heather McKenzie
Legal
Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus
February 18, 2026
·
2 min read
·
Tristan Manalac
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie